Fenbendazole vs Ivermectin for dogs
The short answer
Both are FDA-approved antiparasitics being investigated off-label for anticancer activity, and both are frequently discussed together because their proposed mechanisms differ and do not obviously overlap. Ivermectin has the more directly relevant evidence for dogs — a published in vitro study using canine mammary tumour cells — but carries the MDR1 genetic hazard, which is the single most consequential breed-specific risk on this site and can be fatal in affected dogs at these doses. Fenbendazole has no genetic gatekeeper but does carry documented bone marrow suppression with extended daily dosing, which is why its protocols cycle three days on and four off. Neither should be considered outside a veterinary oncology relationship.
Side by side
| Fenbendazole | Ivermectin | |
|---|---|---|
| Evidence grade | Emerging evidence | Emerging evidence |
| Canine-specific evidence | Animal oncology review literature | In vitro canine mammary tumour study |
| Primary safety hazard | Bone marrow suppression with extended daily dosing | Fatal neurotoxicity in MDR1-mutant dogs |
| Required pre-testing | Baseline CBC and liver panel | MDR1 genetic test before the first dose |
| Schedule | 3 days on, 4 days off | Daily, or 5 days on and 2 off |
| Proposed mechanism | Microtubule destabilisation, glucose metabolism interference | Wnt/beta-catenin, Akt/mTOR and PAK1 modulation |
| Full profile | Fenbendazole for dogs | Ivermectin for dogs |
Safety at a glance
Fenbendazole
Fenbendazole at its labelled three-day deworming dose is one of the safest drugs in veterinary medicine, which is exactly why the extended oncology schedules get discussed so casually — and why that framing is misleading. Pancytopenia has been documented in dogs on extended daily dosing, and hepatic injury has been reported in human self-administration cases. The three-on / four-off cycling and the monthly CBC exist specifically to manage that. It also must not be combined with vincristine or paclitaxel.
Is Fenbendazole safe for dogs? →Ivermectin
Ivermectin's safety in dogs splits cleanly along one genetic line. In dogs without the MDR1 mutation it has decades of use as a heartworm preventive and is generally well tolerated. In dogs carrying the MDR1 (ABCB1) mutation it cannot be cleared from the brain, and at the investigational oncology doses discussed here the resulting neurotoxicity can be fatal. Collies, Australian Shepherds, Shelties, Old English Sheepdogs, Border Collies and herding mixes are the high-risk populations. The cheek-swab test is inexpensive and must precede the first dose.
Is Ivermectin safe for dogs? →Common questions
Which is better for dogs, Fenbendazole or Ivermectin?+
Both are FDA-approved antiparasitics being investigated off-label for anticancer activity, and both are frequently discussed together because their proposed mechanisms differ and do not obviously overlap. Ivermectin has the more directly relevant evidence for dogs — a published in vitro study using canine mammary tumour cells — but carries the MDR1 genetic hazard, which is the single most consequential breed-specific risk on this site and can be fatal in affected dogs at these doses. Fenbendazole has no genetic gatekeeper but does carry documented bone marrow suppression with extended daily dosing, which is why its protocols cycle three days on and four off. Neither should be considered outside a veterinary oncology relationship.
Can Fenbendazole and Ivermectin be used together in dogs?+
Combined protocols using both compounds appear in the literature, and they are more often studied together than as alternatives. Any combination increases the difficulty of attributing an adverse effect to a specific compound, so combining should be a deliberate decision made with your veterinarian rather than a default.
Which has better evidence in dogs, Fenbendazole or Ivermectin?+
Fenbendazole is graded emerging evidence with 5 cited studies; Ivermectin is graded emerging evidence with 4 cited studies. Grades reflect the strength of published literature rather than an opinion about efficacy.
References
- 1.Dogra N, Kumar A, Mukhopadhyay T Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports, 2018. PMID 30093705
- 2.Song B, et al. Fenbendazole: An Anticancer Agent? A Case Series of Self-Administration. Case Reports in Oncology, 2025. PMC12215191
- 3.CANINE STUDYNguyen J, et al. Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Research, 2024. View source
- 4.Leach B, et al. Fenbendazole as a Potential Anticancer Drug. Anticancer Research, 2012. PMC3580766
- 5.Kim YJ, et al. Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma. Current Issues in Molecular Biology, 2023. PMC10670425
- 6.CANINE STUDYZhu M, et al. Ivermectin-induced apoptosis of canine mammary tumor cells through regulation of the cell cycle and WNT signaling. BMC Veterinary Research, 2019. PMC6679554
- 7.Juarez M, Schcolnik-Cabrera A, Duenas-Gonzalez A The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. American Journal of Cancer Research, 2018. PMID 29344093
- 8.Tang M, et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacological Research, 2021. PMC7505114
- 9.Dominguez-Gomez G, et al. Ivermectin as an inhibitor of cancer stem-like cells: antitumor effects at clinically feasible concentrations. Cancer Chemotherapy and Pharmacology, 2020. View source
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.